Report of Foreign Issuer (6-k)
April 06 2018 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: April 2018
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant’s name
into English)
PO Box 318, Tel-Aviv, Israel 6100201
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On April 4, 2018, the
registrant received notice of the resignation of Mr. Ran Nussbaum from his position as a director of the registrant, effective
immediately. Mr. Nussbaum notified the registrant that due to his many commitments to other companies, he needed to reduce the
number of boards on which he served. Mr. Nussbaum does not have any disagreements with the Board, its management or the registrant’s
policies.
This Periodic Report on
Form 6-K is incorporated by reference into the registration statement on Form F-3 (File No. 333-206032) and the registration statements
on Form S-8 (File No. 333-203114 and File No. 333-210459) of the registrant, filed with the Securities and Exchange Commission,
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Bioblast Pharma Ltd.
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Fredric D. Price
|
|
Name:
|
Fredric D. Price
Executive Chairman and Chief Executive Officer
|
Date: April 6, 2018
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Sep 2023 to Sep 2024